Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $604.8 billion.

  • Addex Therapeutics' Net Cash Flow fell 7305.46% to $604.8 billion in Q2 2025 from the same period last year, while for Sep 2025 it was $712.5 billion, marking a year-over-year decrease of 5433.74%. This contributed to the annual value of -$708648.2 for FY2024, which is 7672.66% up from last year.
  • Latest data reveals that Addex Therapeutics reported Net Cash Flow of $604.8 billion as of Q2 2025, which was down 7305.46% from -$556.9 billion recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Net Cash Flow registered a high of $2313.4 billion during Q4 2023, and its lowest value of -$2764.5 billion during Q3 2023.
  • Moreover, its 4-year median value for Net Cash Flow was -$2.4 million (2022), whereas its average is -$4.2 billion.
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Net Cash Flow showed a top increase of 6877117444.11% in 2023 and a maximum decrease of 17849516318.17% in 2023.
  • Quarter analysis of 4 years shows Addex Therapeutics' Net Cash Flow stood at -$3.4 million in 2022, then skyrocketed by 68771174.44% to $2313.4 billion in 2023, then crashed by 71.27% to $664.6 billion in 2024, then dropped by 9.0% to $604.8 billion in 2025.
  • Its Net Cash Flow stands at $604.8 billion for Q2 2025, versus -$556.9 billion for Q1 2025 and $664.6 billion for Q4 2024.